Which GnRH antagonist medication and dosing regimen is recommended preoperatively for a reproductive‑age woman with a left subserosal fibroid undergoing laparoscopic myomectomy?

GnRH Antagonist for Preoperative Fibroid Reduction Before Laparoscopic Myomectomy

For a reproductive-age woman with a subserosal fibroid undergoing laparoscopic myomectomy, administer a GnRH agonist (such as leuprolide acetate) for 3–4 months preoperatively to achieve maximal fibroid volume reduction of up to 50%, making the surgical procedure technically easier with improved visualization and reduced operative complexity. 1

Recommended Preoperative Protocol

Primary Agent Selection

• GnRH agonists (e.g., leuprolide acetate) are the established standard for preoperative fibroid reduction, achieving up to 50% volume reduction over 3 months of treatment and significantly reducing uterine volume before surgery. 1
• Oral GnRH antagonists (relugolix, elagolix, linzagolix) are FDA-approved for fibroid-related heavy menstrual bleeding but are positioned as second-line medical management for symptom control rather than preoperative preparation. 2

Optimal Treatment Duration and Timing

• Administer GnRH agonist for 3–4 months prior to surgery to achieve maximal fibroid volume reduction. 1
• Schedule surgery promptly after completing the 3–4 month course, as fibroids rapidly return to pretreatment size after GnRH discontinuation. 1

Add-Back Therapy Considerations

• If treatment extends beyond 3 months, add hormone add-back therapy (low-dose estrogen-progestin) to prevent bone mineral density loss while maintaining fibroid volume reduction. 1
• GnRH agonist monotherapy without add-back should be limited to 3–6 months to avoid severe hypoestrogenic symptoms and clinically significant bone loss. 3

Adjunctive Measures

• Provide concurrent iron supplementation to optimize preoperative hemoglobin, particularly if the patient has experienced heavy menstrual bleeding. 1

Alternative GnRH Antagonist Data (Research Context)

Rapid-Acting GnRH Antagonists for Short-Term Preoperative Use

While GnRH agonists remain the guideline-recommended standard, research demonstrates that GnRH antagonists can achieve rapid fibroid reduction:

• Cetrorelix (3 mg subcutaneously every 4 days) achieved a mean 31% reduction in fibroid size after only 16 days in six of ten patients, with deep and sustained suppression of gonadotrophins and sex steroids, minimal blood loss during surgery, and no side effects. 4
• Ganirelix (2 mg daily subcutaneously) resulted in median maximal leiomyoma size reduction at 19 days (range 1–65 days), with maximal size reduction of -42.7% by ultrasound and -29.2% by MRI, and comparable uterine size reductions. 5
• Cetrorelix depot formulation (60 mg intramuscularly on cycle day 2, followed by 30 or 60 mg at day 21 or 28) achieved mean shrinkage of 33.5% of largest fibroid volume after 6–8 weeks, with 31.3% shrinkage already observed after 14 days, avoiding any initial flare-up effect. 6

Oral GnRH Antagonists: Efficacy Profile

• Relugolix induces dose-dependent decrease in menstrual blood loss with faster reduction of heavy menstrual bleeding and greater shrinkage in fibroid volume compared to GnRH agonist treatment. 7
• Oral GnRH antagonists (relugolix, elagolix, linzagolix) alone and in combination with estradiol/norethindrone acetate showed significantly better efficacy than placebo in improving bleeding, discomfort, uterine/leiomyoma sizes, and quality of life. 8
• Meta-analysis of 11 randomized trials (4164 patients) demonstrated GnRH antagonists versus placebo achieved superior control of uterine bleeding (RR = 5.09), percentage reduction of fibroid volume (MD = -27.36%), and lower reduction of bone density (MD -0.35). 9

Critical Limitations and Caveats

Why GnRH Agonists Remain the Standard for Preoperative Use

• Current guidelines specifically recommend GnRH agonists—not oral GnRH antagonists—for preoperative fibroid reduction. 1
• Oral GnRH antagonists are FDA-approved and guideline-endorsed for symptom management (heavy menstrual bleeding control), not specifically for preoperative volume reduction prior to myomectomy. 2, 10
• No clinically meaningful volume reductions were found with GnRH antagonist combination preparations in recent critical reviews, and long-term safety data concerning modest but stable bone mineral density decline need further addressing. 11

Fertility Considerations

• Fertility is suppressed during GnRH treatment (both agonists and antagonists) but returns after cessation. 1
• For a reproductive-age woman, this temporary suppression is acceptable for the 3–4 month preoperative window.

Inappropriate Alternatives

• Oral contraceptive pills are effective for managing bleeding symptoms but do not reduce fibroid size and are first-line therapy for symptom control in women with small fibroids, not for preoperative volume reduction. 1
• Levonorgestrel IUDs are the most effective first-line treatment for reducing menstrual blood loss but do not shrink fibroids, addressing bleeding symptoms only, not surgical preparation. 1
• Progestins may help with bleeding control but lack evidence for significant fibroid volume reduction needed for surgical preparation and are not recommended as preoperative therapy for myomectomy. 1

Practical Implementation Algorithm

1. Initiate GnRH agonist (leuprolide acetate) on cycle day 2–3 for a planned 3–4 month course. 1
2. Begin iron supplementation immediately if patient has anemia from heavy menstrual bleeding. 1
3. If treatment will extend beyond 3 months, add low-dose estrogen-progestin add-back therapy at month 3 to prevent bone loss. 1
4. Schedule laparoscopic myomectomy for 1–2 weeks after completing the 3–4 month GnRH course to capitalize on maximal fibroid shrinkage before regrowth occurs. 1
5. Counsel patient that fertility will be temporarily suppressed during treatment but will return after surgery. 1